Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Iraq Healthcare Wire.
Press releases published on July 17, 2025
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
GlobeNewswire
·
July 17, 2025
€7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 million Tiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit …
Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non-licenciés
GlobeNewswire
·
July 17, 2025
17 juillet 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui la signature d’un nouvel accord majeur …
Press Release: Sanofi announces extension of Blueprint tender offer
GlobeNewswire
·
July 17, 2025
Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration date of its tender offer to purchase all of the outstanding …
Communiqué de presse : Sanofi annonce la prolongation de l’offre publique d’achat sur Blueprint
GlobeNewswire
·
July 17, 2025
Sanofi annonce la prolongation de l’offre publique d’achat sur Blueprint Paris, le 17 juillet 2025. Sanofi annonce aujourd'hui que Rothko Merger Sub, Inc., une filiale détenue à 100 % par Sanofi, a prolongé la date d'expiration de son offre publique d' …
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
GlobeNewswire
·
July 17, 2025
ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting …